J. Hutchinson

发表

Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype 2 receptor.

Merryl D. Cramer, M. F. Gardner, J. James, 2005, Bioorganic & medicinal chemistry letters.

Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.

J. Falgueyret, S. Charleson, J. Evans, 1995, Journal of medicinal chemistry.

3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2).

A. Pinkerton, M. F. Gardner, J. James, 2005, Bioorganic & medicinal chemistry letters.

Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 1: Identification and synthesis of phenyl-tetrazolyl acetophenones.

A. Pinkerton, J. Vernier, J. Hutchinson, 2004, Bioorganic & medicinal chemistry letters.

Pyrimidine methyl anilines: selective potentiators for the metabotropic glutamate 2 receptor.

E. Hu, N. Cosford, A. Pinkerton, 2004, Bioorganic & medicinal chemistry letters.

Characterization of the arachidonate and ATP binding sites of human 5-lipoxygenase using photoaffinity labeling and enzyme immobilization.

J. Falgueyret, D. Riendeau, J. Hutchinson, 1995, Biochemistry.

Pharmacodynamics and Pharmacokinetics of AM103, a Novel Inhibitor of 5‐Lipoxygenase‐Activating Protein (FLAP)

D. Lorrain, P. Prasit, J. Evans, 2010, Clinical pharmacology and therapeutics.

Diaryl substituted pyrazoles as potent CCR2 receptor antagonists.

M. Struthers, J. Demartino, A. Pinkerton, 2007, Bioorganic & medicinal chemistry letters.

Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.

P. Coleman, C. Leu, J. Huff, 2003, Journal of medicinal chemistry.

Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.

P. Coleman, C. Leu, G. Wesolowski, 2004, Journal of medicinal chemistry.

Nonpeptide αvβ3 Antagonists. Part 11: Discovery and Preclinical Evaluation of Potent αvβ3 Antagonists for the Prevention and Treatment of Osteoporosis

P. Coleman, C. Leu, G. Wesolowski, 2004 .

Disposition of a novel and potent αvβ3 antagonist in animals, and extrapolation to man

S. Rodan, J. Lin, T. Prueksaritanont, 2004 .

Potent, non-thiol inhibitors of farnesyltransferase.

D. Pompliano, S. Graham, J. Hutchinson, 1998, Bioorganic & medicinal chemistry letters.

Pharmacological Characterization of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation

Jilly F. Evans, D. Lorrain, C. King, 2009, Journal of Pharmacology and Experimental Therapeutics.

Mouse Models of Liver Fibrosis

Andiliy G. Lai, C. King, J. Hutchinson, 2016 .

Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, European journal of pharmacology.

New method for microdetermination of blood ammonia by use of cation exchange resin.

J. Hutchinson, D. Labby, 1962, Journal of Laboratory and Clinical Medicine.

Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.

Jilly F. Evans, C. King, J. Bentley, 2013, British journal of clinical pharmacology.

Leukotriene B4 inhibitors: US2009054466; US2009227603 and US2009253684

J. Hutchinson, 2010, Expert opinion on therapeutic patents.

Pharmacological Blockade of the DP2 Receptor Inhibits Cigarette Smoke-Induced Inflammation, Mucus Cell Metaplasia, and Epithelial Hyperplasia in the Mouse Lung

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Journal of Pharmacology and Experimental Therapeutics.

5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of medicinal chemistry.

DP2 (CRTh2) Antagonism Reduces Ocular Inflammation Induced by Allergen Challenge and Respiratory Syncytial Virus

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, International Archives of Allergy and Immunology.

Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, European journal of pharmacology.

5-Lipoxygenase-activating Protein (FLAP) Inhibitors Are Superior To 5-lipoxygenase (5-LO) Inhibitors For Inhibition Of Leukotriene Synthesis In Rat Lung

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, ATS 2010.

5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Bioorganic & medicinal chemistry letters.

Criteria for the identification of non-redox inhibitors of 5-lipoxygenase.

J. Falgueyret, D. Riendeau, J. Hutchinson, 1993, Biochemical pharmacology.

A Novel 5-Lipoxygenase-Activating Protein Inhibitor, AM679, Reduces Inflammation in the Respiratory Syncytial Virus-Infected Mouse Eye

Jilly F. Evans, D. Lorrain, S. Barik, 2009, Clinical and Vaccine Immunology.

5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Bioorganic & medicinal chemistry letters.

5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).

Jilly F. Evans, D. Lorrain, P. Prasit, 2009, Journal of medicinal chemistry.

Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein.

J. Falgueyret, D. Riendeau, R. Young, 2008, Bioorganic & medicinal chemistry letters.

Pharmacodynamics, Pharmacokinetics, and Safety of AM211: A Novel and Potent Antagonist of the Prostaglandin D2 Receptor Type 2

K. Holme, C. King, J. Hutchinson, 2012, Journal of clinical pharmacology.

Development of L-689,065 - the prototype of a new class of potent 5-lipoxygenase inhibitors

D. Riendeau, P. Prasit, S. Charleson, 1992 .

Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.

D. Riendeau, C. Brideau, C. Chan, 1999, Bioorganic & medicinal chemistry letters.

Inhibition of synovial LTB4 production by a specific leukotriene biosynthesis inhibitor, MK‐0591, in a rabbit model of joint inflammation

C. Brideau, D. Guévremont, J. Hutchinson, 1993 .

Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis

Jilly F. Evans, Andiliy G. Lai, C. King, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia.

L. Bristow, J. James, T. Kamenecka, 2005, Bioorganic & medicinal chemistry letters.

Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

Pharmacology of AM211, a Potent and Selective Prostaglandin D2 Receptor Type 2 Antagonist That Is Active in Animal Models of Allergic Inflammation

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.

Jilly F. Evans, D. Lorrain, P. Prasit, 2009, Bioorganic & medicinal chemistry letters.

Diaryl ether inhibitors of farnesyl-protein transferase.

A. W. Shaw, T. Ciccarone, J. Davide, 1997, Bioorganic & medicinal chemistry letters.

A new class of leukotriene biosynthesis inhibitors: The discovery of MK0591

D. Riendeau, R. Young, P. Prasit, 1992 .

Non‐peptide fibrinogen receptor antagonists. 41. The synthesis of [3H]L‐756,568

G. Hartman, J. Hutchinson, T. Hamill, 1998 .

Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements.

P. Coleman, C. Leu, S. Rodan, 2002, Bioorganic & medicinal chemistry letters.

Ligands to the integrin receptor αvβ3

J. Hutchinson, M. Duggan, 2000 .

Enantiospecific synthesis of estrone

J. Hutchinson, T. Money, 1985 .

Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators.

A. Pinkerton, J. James, U. Campbell, 2005, Bioorganic & medicinal chemistry letters.

Enantiospecific synthetic approach to C,D-ring system of steroids with functionalized side-chains

J. Hutchinson, T. Money, 1986 .

Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.

R. Gould, G. Hartman, J. Hutchinson, 1996, Journal of medicinal chemistry.

A new synthetic route to (±)-forskolin

D. Cheshire, J. Hutchinson, G. Pattenden, 1989 .

Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.

J. Falgueyret, D. Riendeau, C. Brideau, 1994, Journal of medicinal chemistry.

Nonpeptide glycoprotein IIB/IIIA inhibitors: 18. Indole alpha-sulfonamide acids are potent inhibitors of platelet aggregation

R. Gould, G. Hartman, J. Hutchinson, 1997 .

Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists.

J. Barrow, R. Freidinger, P. Nantermet, 2001, Bioorganic & medicinal chemistry letters.

Ring cleavage of camphor derivatives: formation of chiral synthons for natural product synthesis

J. Hutchinson, T. Money, S. E. Piper, 1986 .

Dichotomous reactivity in stannane and cobalt mediated radical cyclisations

J. Hutchinson, G. Pattenden, M. Begley, 1987 .

Tandem radical cyclisation - intramolecular Mukaiyama aldolisation approach to forskolin

J. Hutchinson, G. Pattenden, P. Myers, 1987 .

Silaketals as tethers in intramolecular radical cyclisations

J. Gillard, J. Hutchinson, T. Daynard, 1991 .

Formation of a novel thiopyranoindole ring system

J. Hutchinson, D. Macdonald, J. Scheigetz, 1992 .

Use of camphor in steroid synthesis: a new approach to optically active trans-hydrindane derivatives

J. Hutchinson, T. Money, S. E. Piper, 1984 .

Development of urea-cycle enzymes in the juvenile rat: Effect of long-term administration of L-monosodium glutamate and ammonium acetate

J. Hutchinson, D. Labby, 1965, The American Journal of Digestive Diseases.

Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells

K. Vuori, N. Cosford, E. Pasquale, 2021, The Journal of biological chemistry.

N-arylpiperazinone inhibitors of farnesyltransferase: discovery and biological activity.

J. Huff, J. Davide, N. Kohl, 1999, Journal of medicinal chemistry.

Incorporation of 3 H-uridine into RNA of toad bladder epithelial cells. Method of determination.

J. Hutchinson, G. Porter, 1970, Biochemical medicine.

The effect of temperature and substrate concentration on the kinetics of (6- 3 H)uridine incorporation into RNA of toad bladder epithelial cells: the role of aldosterone.

J. Hutchinson, G. Porter, 1972, Biochimica et biophysica acta.

Overestimation of DNA by ultraviolet measurement: a correction factor for toad bladder epithelial cells.

J. Hutchinson, G. Porter, 1970, Biochemical medicine.

What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases.

Jilly F. Evans, A. Ferguson, R. Mosley, 2008, Trends in pharmacological sciences.

Seeing the future of bioactive lipid drug targets.

Jilly F. Evans, J. Hutchinson, 2010, Nature chemical biology.

Gram-negative sepsis in neonates: a nursery outbreak due to hand carriage of Citrobacter diversus.

J. Hutchinson, M. F. Parry, N. A. Brown, 1980, Pediatrics.

Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding

Jilly F. Evans, J. Hutchinson, Jeffrey M. Schaub, 2015, Molecular Pharmacology.

Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding s

Jilly F. Evans, J. Hutchinson, G. Bain, 2015 .

Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.

Jilly F. Evans, C. King, J. Hutchinson, 2017, ACS medicinal chemistry letters.

Non-peptide αvβ3 antagonists. Part 7: 3-Substituted tetrahydro-[1,8]naphthyridine derivatives

P. Coleman, C. Leu, S. Rodan, 2004 .

Waterborne Legionella bozemanii and nosocomial pneumonia in immunosuppressed patients.

D. Folta, J. Hutchinson, M. F. Parry, 1985, Annals of internal medicine.

Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816.

J. Falgueyret, D. Riendeau, C. Brideau, 1993, Journal of medicinal chemistry.

In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.

T. Baillie, T. Prueksaritanont, G. Hartman, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).

Jilly F. Evans, Andiliy G. Lai, D. Mackenna, 2017, Journal of medicinal chemistry.

Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.

T. Kamenecka, C. Bonnefous, Janice Chung, 2005, Bioorganic & medicinal chemistry letters.

Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 2: 4-thiopyridyl acetophenones as non-tetrazole containing mGlu2 receptor potentiators.

A. Pinkerton, J. James, J. Vernier, 2004, Bioorganic & medicinal chemistry letters.

Formation of synthetically useful camphor derivatives: mechanistic aspects

J. Hutchinson, T. Money, W. M. Dadson, 1990 .

Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid.

J. Falgueyret, D. Riendeau, C. Brideau, 1994, Journal of Medicinal Chemistry.

Thiopyrano(2,3,4-cd)indoles as 5-Lipoxygenase Inhibitors: Synthesis, Biological Profile, and Resolution of 2-(2-(1-(4-Chlorobenzyl)-4- methyl-6-((5-phenylpyridin-2-yl)methoxy)-4,5-dihydro-1H-thiopyrano(2,3, 4-cd)indol-2-yl)ethoxy)butanoic Acid.

J. Falgueyret, D. Riendeau, C. Brideau, 1994 .

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

Dipyridyl amines: potent metabotropic glutamate subtype 5 receptor antagonists.

T. Kamenecka, C. Bonnefous, J. Vernier, 2005, Bioorganic & medicinal chemistry letters.

A formal enantiospecific synthesis of California red scale pheromone

J. Hutchinson, T. Money, 1985 .

Stereoselectivity of C(3)-methylation of camphor and derivatives

J. Hutchinson, T. Money, 1984 .